Alendronate treatment for fibrous dysplasia, a rare skeletal disorder .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
A Randomized, Double Blind, Placebo-Controlled Trial of Alendronate Treatment for Fibrous Dysplasia of Bone
J Clin Endocrinol Metab. 2014 Nov;99(11):4133-40.40 patients (24 adults and 16 children) with fibrous dysplasia (FD) were randomized to either receive alendronate administration in 6-month cycles for 24 months or placebo. The results revealed that in the alendronate group, NTX-telopeptides markers significantly declined at 18 months, however no significant difference in osteocalcin was observed between groups. Furthermore, areal bone mineral density in both normal lumbar bone and predetermined FD regions significantly increased in the alendronate group at 24 months, but not at 12 months. There was no significant difference in pain and function measures between groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
